Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention

(2020) Sarah M. Bartsch et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

(2020) Silvia Stringhini et al.   LANCET

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

A minimal common outcome measure set for COVID-19 clinical research

(2020) John C Marshall et al.   LANCET INFECTIOUS DISEASES

COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland

(2020) Alvin Richards-Belle et al.   INTENSIVE CARE MEDICINE

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial

(2015) D. Pace et al.   BMJ-British Medical Journal

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial

(2015) D. Pace et al.   BMJ-British Medical Journal